Hi KTThank you for your re-post of this Twitter link. It has...

Hi KT

Thank you for your re-post of this Twitter link.

It has set me thinking. This article covers some of the early in vivo and in vitro work done on the ‘refined’ CF33 virus, and its add-ons. Certainly not the latest Phase 1 work we are hearing about, via company announcement and roadshows.

The Journal for ImmunoTherapy of Cancer is the official journal of the Society for Immunotherapy of Cancer (SITC) and is quite likely the most important cancer journal available to researchers. It is open access and is always peer-reviewed. Let’s just say it’s a very ‘big deal’ in the cancer research space.

Now we, who are invested, or at least interested in what IMU is doing across the CF33 suite, are well aware of the research mentioned in this article. We know of this amazing science via the IMU ‘info-stream’ that includes, newsletters, trial updates, roadshows and the like.

What I am wondering is how much is actually known about CF33, outside the IMU world? In other words, the huge world of cancer research, certainly outside of little Oz.

Sometimes I wonder if we are too inward looking, and as a result expect instant reaction on the ASX, to the IMU ‘info-stream’. Perhaps we assume that the amazing CF33 viruses are known worldwide, by every researcher in the field. And it’s a HUGE field. It’s certainly not that the City of Hope (a world leader in cancer treatment and research), is hiding its potential. It may just be that the cancer research space is so enormous, with so many competing interests and hopeful treatments, it’s hard to draw any significant attention to the work of IMU.

So, perhaps soon, with articles appearing in the JITC, and invitations to speak at major investment conferences, and a possible NASDAQ listing, we may see greater interest in what IMU is actually achieving. Maybe the recent upward movement we have witnessed this week, is part of a wider ‘awakening’ about IMU and its considerable potential. Who knows. Time will tell, I guess. We live in hope.

In the long run, it will be the science that will speak the loudest. Perhaps our voice is only now being heard.

This is not investment advice, just the opinion of oneposter.